PP
CPRX

PDT Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

PDT Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,664
Closed -$431K – 764
2024
Q4 		$431K Buy
20,664
+1,030
+5% +$22.1K 0.04% 511
2024
Q3 		$390K Buy
+19,634
New +$364K 0.03% 559
2022
Q4 		– Sell
-46,943
Closed -$602K – 681
2022
Q3 		$602K Buy
46,943
+7,748
+20% +$91.8K 0.09% 381
2022
Q2 		$275K Buy
39,195
+478
+1% +$3.51K 0.02% 756
2022
Q1 		$321K Buy
+38,717
New +$274K 0.03% 705
2020
Q3 		– Sell
-276,900
Closed -$1.28M – 738
2020
Q2 		$1.28M Sell
276,900
-50,100
-15% -$225K 0.09% 246
2020
Q1 		$1.26M Sell
327,000
-68,782
-17% -$282K 0.1% 203
2019
Q4 		$1.48M Buy
395,782
+210,977
+114% +$987K 0.09% 223
2019
Q3 		$981K Buy
+184,805
New +$985K 0.06% 283

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

PDT Partners's CPRX Position: Q1 2025 in Review

PDT Partners sold out of Catalyst Pharmaceutical (CPRX) in Q1 2025, closing a stake of 20,664 shares — an estimated $431K sold.

PDT Partners first reported a position in CPRX in Q3 2019 and held it in 9 quarters. The position peaked at $1.48M in Q4 2019. 371 funds tracked by Wall St. Rank hold CPRX as of Q1 2025.

  • PDT Partners reported no remaining Catalyst Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • PDT Partners sold 20,664 Catalyst Pharmaceutical shares in Q1 2025, an estimated $431K.
  • PDT Partners first reported a position in Catalyst Pharmaceutical in Q3 2019 and held it in 9 quarters.
  • PDT Partners's Catalyst Pharmaceutical position peaked at $1.48M in Q4 2019.
  • 371 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2025.

Based on PDT Partners's 13F filing for Q1 2025, filed 15 May 2025.